Products Affected - Description

• • Cisplatin injection, Accord, 1 mg/mL, 100 mL vial, 1 count, NDC 16729-0288-38
  • Cisplatin injection, Fresenius Kabi, 1 mg/mL, 50 mL vial, 1 count, NDC 63323-0103-51
  • Cisplatin injection, Hikma, 1 mg/mL, 100 mL vial, 1 count, NDC 00143-9505-01
  • Cisplatin injection, Hikma, 1 mg/mL, 50 mL vial, 1 count, NDC 00143-9504-01
  • Cisplatin injection, Sagent, 1 mg/mL, 100 mL vial, 1 count, NDC 25021-0253-51
  • Cisplatin injection, WG Critical Care, 1 mg/mL, 200 mL vial, 1 count, NDC 44567-0511-01

Reason for the Shortage

• • Accord did not provide a reason for the shortage.
  • Fresenius Kabi did not provide a reason for the shortage.
  • Hikma did not provide a reason for the shortage.
  • Sagent did not provide a reason for the shortage.
  • Teva has cisplatin available.
  • WG Critical Care did not provide a reason for the shortage.

Available Products

• • Cisplatin injection, Accord, 1 mg/mL, 50 mL vial, 1 count, NDC 16729-0288-11
  • Cisplatin injection, Fresenius Kabi, 1 mg/mL, 100 mL vial, 1 count, NDC 63323-0103-65
  • Cisplatin injection, Fresenius Kabi, 1 mg/mL, 200 mL vial, 1 count, NDC 63323-0103-64
  • Cisplatin injection, Sagent, 1 mg/mL, 50 mL vial, 1 count, NDC 25021-0253-50
  • Cisplatin injection, Teva, 1 mg/mL, 100 mL vial, 1 count, NDC 00703-5748-11
  • Cisplatin injection, Teva, 1 mg/mL, 50 mL vial, 1 count, NDC 00703-5747-11
  • Cisplatin lyophilized powder for injection, WG Critical Care, 50 mg vial, 1 count, NDC 44567-0530-01

• • Accord has cisplatin 1 mg/mL 100 mL vials on back order and the company estimates a release date of 1st quarter 2026.
  • Fresenius Kabi has short-dated cisplatin 1 mg/mL 50 mL vials available with an expiration date of < 8 months.
  • Hikma has cisplatin 1 mg/mL 100 mL vials on back order and the company estimates a release date of mid- to late-May 2026. There are short-dated 50 mL vials available with an expiration date of < November 2026.
  • Sagent has cisplatin 1 mg/mL 100 mL vials on back order and the company estimates a release date of early-February 2026.
  • WG Critical Care has cisplatin 1 mg/mL 200 mL vials on back order and the company cannot estimate a release date.

• • The Society of Gynecologic Oncology has a statement on conservation strategies during this shortage. This statement is available at: https://www.sgo.org/news/drugshortage/

• • Consider evaluating the health-care system's total supply of cisplatin before beginning patients on combination chemotherapy regimens containing cisplatin. If adequate supplies are not available, select an alternative regimen.
  • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for cisplatin.
  • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
  • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
  • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.